{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"43","value":"14"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"Objective response rate of the combination of Rituximab and TMZ","dispersionType":"95% Confidence Interval","groups":[{"description":"IV Rituximab 750mg/m2 single infusion every week for up to 4 weeks.\n\nInduction: Rituximab (750mg/m2) Day 1, 8, 15 and 22 and Temozolomide \\[TMZ\\] (150mg/m2) days 1-7 and 15-21, followed by six cycles of consolidation TMZ 150-200mg/m2 x5/28days, followed by maintenance with methylprednisolone (1g IV every 28days) until progression\n\nrituximab: given IV days 1,8, 15 and 22\n\nmethylprednisolone: 2hr IV every 28 days post consolidation cycles of Temozolomide (TMZ) (6 cycles TMZ = Consolidation cycles)\n\ntemozolomide: Induction Days 1-7 and 15-21 (150mg/m2 PO) Consolidation days 1-5 every 28 days X 6 cycles","id":"OG000","title":"IV Rituximab"}],"paramType":"NUMBER","populationDescription":"2 patients were not evaluable, one died prematurely and the other withdrew consent before the first scan (during induction cycle)","reportingStatus":"POSTED","timeFrame":"2 months","title":"Percentage of Participants With Objective Response","type":"PRIMARY","unitOfMeasure":"percent of participants"}